Skip to main content

AstraZeneca vs Cloudflare: Founders, CEOs and History

AstraZeneca was founded in 1999 by Sir David Barnes, Håkan Mogren and is led by Pascal Soriot. Cloudflare was founded in 2009 by Matthew Prince, Michelle Zatlyn, Lee Holloway and is led by Matthew Prince.

Company facts

AstraZeneca

Founded
1999
Headquarters
Cambridge, England
Current CEO
Pascal Soriot
Employees
96,100

Cloudflare

Founded
2009
Headquarters
San Francisco, California
Current CEO
Matthew Prince
Employees
5,156

Founders

AstraZeneca

  • Sir David Barnes

    Sir David Barnes was chief executive of Zeneca Group plc, the company created when Imperial Chemical Industries demerged its pharmaceuticals, agrochemicals and specialty chemicals businesses in 1993, and he led the Zeneca side of the negotiations that produced…

  • Håkan Mogren

    Håkan Mogren was chief executive of Astra AB and negotiated the Swedish side of the 1999 merger with Zeneca Group alongside Sir David Barnes.

AstraZeneca founders in full

Cloudflare

  • Matthew Prince

    Matthew Prince is Cloudflare's co-founder, CEO, and board chair. In 2004 he and Lee Holloway built Project Honey Pot, which let website owners track spammers harvesting email addresses but could not stop them.

  • Michelle Zatlyn

    Michelle Zatlyn is Cloudflare's co-founder, President, and Chief Operating Officer, and a member of its board. She met Matthew Prince at Harvard Business School, where the two developed the business plan that became Cloudflare in 2009.

  • Lee Holloway

    Lee Holloway co-founded Cloudflare in 2009 and was its first lead engineer and systems architect. He had earlier built Project Honey Pot with Matthew Prince starting in 2004, and he designed much of Cloudflare's early software infrastructure.

Cloudflare founders in full

CEOs and their tenures

AstraZeneca

  1. Tom McKillop1999–2006

    Chief Executive Officer

    McKillop led AstraZeneca from the 1999 merger through the Nexium launch and the first biotech acquisitions.

    Source
  2. David Brennan2006–2012

    Chief Executive Officer

    Brennan led AstraZeneca through the start of the patent cliff and favoured cost-cutting and share buybacks over pipeline investment.

    Source
  3. Pascal Soriot2012–present

    Chief Executive Officer

    Soriot took over a company whose revenue was falling toward $25.7 billion and has taken Total Revenue to $58.7 billion, with 16 blockbuster medicines.

    Source
AstraZeneca CEO history in full

Cloudflare

  1. Matthew Prince2009–present

    Co-Founder, Chief Executive Officer, and Chair

    Co-founded Cloudflare in 2009, led it through its September 2019 NYSE IPO, and has grown annual revenue past $2 billion (2025) while expanding from web security into Zero Trust, developer, and AI services.

    Source
  2. Michelle Zatlyn2009–present

    Co-Founder, President, and Chief Operating Officer

    Co-founded Cloudflare in 2009 with Matthew Prince and Lee Holloway and, as President and COO, has led operations and company-building as Cloudflare scaled to more than 5,000 employees.

    Source
  3. Thomas Seifert2017–present

    Chief Financial Officer

    As CFO, he consistently delivered high revenue growth while carefully controlling capital expenditures, allowing Cloudflare to heavily invest in its serverless Edge computing network.

    Source
Cloudflare CEO history in full

Timeline: AstraZeneca and Cloudflare side by side

  1. 1913AstraZeneca

    Astra AB Founded in Södertälje, Sweden

    400 doctors and apothecaries establish Astra AB to manufacture pharmaceuticals for the Swedish market, creating the foundation for what would become one of Europe's largest drug companies.

  2. 1993AstraZeneca

    Zeneca Group Spun Off from ICI

    Imperial Chemical Industries demerges its pharmaceuticals and agrochemicals businesses to form Zeneca Group PLC, with initial products including Zestril, Nolvadex, and Zoladex generating approximately $3.2 billion in annual sales.

  3. 1999AstraZeneca

    Astra and Zeneca Merge to Form AstraZeneca

    The all-share merger of equals completes on 6 April 1999, creating AstraZeneca PLC.

  4. 2000AstraZeneca

    Nexium Launch Replaces Prilosec

    AstraZeneca launches Nexium (esomeprazole), the single-isomer successor to Losec/Prilosec, in Europe in 2000 and in the United States in 2001 after FDA approval on 20 February 2001.

  5. 2006AstraZeneca

    Acquisition of Cambridge Antibody Technology

    AstraZeneca agrees in May 2006 to buy Cambridge Antibody Technology for 1,320 pence a share, valuing the UK biotech at 702 million pounds or about $1.32 billion.

  6. 2007AstraZeneca

    Acquisition of MedImmune for $15.6 Billion

    AstraZeneca acquires MedImmune for $15.6 billion, entering the biologics market and gaining the Synagis respiratory syncytial virus franchise and antibody technology platforms. The Gaithersburg facility becomes one of three global R&D centres.

  7. 2009Cloudflare

    Cloudflare Founded

    Matthew Prince, Michelle Zatlyn, and Lee Holloway founded Cloudflare, building on the Project Honey Pot spam-tracking project.

  8. 2010Cloudflare

    TechCrunch Disrupt Launch

    Cloudflare launched publicly at TechCrunch Disrupt in San Francisco in September 2010, offering free website protection and acceleration.

  9. 2012AstraZeneca

    Pascal Soriot Appointed CEO

    Pascal Soriot joins AstraZeneca as Chief Executive Officer on October 1, 2012, with a base salary of $1.4 million and a mandate to reverse declining revenue and R&D productivity through science-led investment.

  10. 2014AstraZeneca

    Pfizer Hostile Takeover Rejected

    AstraZeneca's board rejects a $117 billion hostile takeover offer from Pfizer, with Soriot arguing that the undervaluation would destroy long-term shareholder value and pipeline potential.

  11. 2014AstraZeneca

    Acquisition of Almirall Respiratory Portfolio

    AstraZeneca acquires the respiratory portfolio of Spanish pharmaceutical company Almirall for approximately $2.1 billion, strengthening the company's position in COPD and asthma with products including Eklira and pipeline candidates that become Breztri.

  12. 2014Cloudflare

    Universal SSL and Project Galileo

    Cloudflare gave free SSL certificates to all customers with Universal SSL and launched Project Galileo to protect at-risk nonprofits and journalists for free.

  13. 2015AstraZeneca

    Tagrisso Approved for EGFR-Mutated Lung Cancer

    The FDA approves Tagrisso (osimertinib) in November 2015 for metastatic EGFR T790M mutation-positive non-small cell lung cancer, the first product from Soriot's reinvestment strategy to reach market.

  14. 2017AstraZeneca

    Imfinzi Approved Based on PACIFIC Trial

    The FDA approves Imfinzi (durvalumab) for unresectable stage III non-small cell lung cancer after chemoradiation, based on PACIFIC trial data showing survival benefits.

  15. 2017Cloudflare

    Cloudflare Workers Announced

    Cloudflare introduced Workers, a serverless platform built on V8 isolates that lets developers run code across its network.

  16. 2019Cloudflare

    NYSE IPO

    Cloudflare completed its IPO on the New York Stock Exchange under the ticker NET in September 2019 at $15 per share, raising about $525 million.

  17. 2020AstraZeneca

    COVID-19 Vaccine Development with Oxford University

    AstraZeneca partners with the University of Oxford to develop and manufacture the Vaxzevria COVID-19 vaccine, distributing billions of doses globally at nonprofit pricing during the pandemic peak.

  18. 2020Cloudflare

    Cloudflare One Launched

    Cloudflare bundled its Zero Trust access, secure web gateway, and network services into Cloudflare One, its SASE platform.

  19. 2021AstraZeneca

    Acquisition of Alexion Pharmaceuticals for $39 Billion

    AstraZeneca completes the $39 billion acquisition of Alexion on July 21, 2021, entering the rare disease market with Soliris and Ultomiris and creating a dedicated rare disease unit headquartered in Boston.

  20. 2022Cloudflare

    Area 1 Security and R2 General Availability

    Cloudflare acquired email security company Area 1 Security for about $162 million and made R2 zero-egress object storage generally available.

  21. 2023AstraZeneca

    CinCor Pharma Acquired for up to $1.8 Billion

    AstraZeneca agrees on 9 January 2023 to acquire CinCor Pharma for up to $1.8 billion, $26 per share in cash plus a $10 per share contingent value right, to gain baxdrostat, an aldosterone synthase inhibitor for resistant hypertension.

  22. 2024AstraZeneca

    Total Revenue Reaches $54.073 Billion

    AstraZeneca reports Total Revenue of $54.073 billion for fiscal year 2024, an 18% increase at actual rates and 21% at constant exchange rates, with 16 blockbuster medicines, 74 regulatory events, and 24 pipeline progression events.

  23. 2024AstraZeneca

    Fusion Pharmaceuticals and Gracell Acquisitions

    AstraZeneca acquires Fusion Pharmaceuticals for $2 billion to access radiopharmaceutical technology and Gracell Biotechnologies for $1.2 billion for cell therapy manufacturing, expanding modality diversity into radiopharmaceuticals and CAR-T.

  24. 2024Cloudflare

    Revenue Reaches $1.67 Billion

    Cloudflare reported 2024 revenue of $1.67 billion and free cash flow of $166.9 million.

  25. 2025AstraZeneca

    Total Revenue Reaches $58.739 Billion

    AstraZeneca reports Total Revenue of $58.739 billion for fiscal year 2025, an 8% increase at constant exchange rates, with 16 positive Phase III readouts, 43 major market approvals, and a commitment to invest $50 billion in U.S. manufacturing by 2030.

  26. 2025AstraZeneca

    EsoBiotec Acquired for Up to $1 Billion

    AstraZeneca acquires Belgian biotech EsoBiotec for up to $1 billion to access in vivo cell therapy technology, eliminating the need for ex vivo manufacturing in CAR-T therapies.

  27. 2025AstraZeneca

    $50 Billion US Manufacturing and R&D Commitment

    AstraZeneca announces on 21 July 2025 that it will invest $50 billion in United States manufacturing and research by 2030, including a new Virginia facility later raised to $4.5 billion.

  28. 2025Cloudflare

    Revenue Passes $2 Billion

    Cloudflare reported 2025 revenue of $2.17 billion (+29.8%) and closed its largest contract ever, averaging $42.5 million per year in ACV.

  29. 2026AstraZeneca

    Ordinary Shares Begin Trading on the NYSE

    AstraZeneca ordinary shares start trading on the New York Stock Exchange on 2 February 2026 under the ticker AZN, after the American Depositary Share programme and certain debt securities stopped trading on Nasdaq on 30 January 2026.

  30. 2026AstraZeneca

    Baxfendy Approved in the US for Hypertension

    The FDA approves Baxfendy (baxdrostat) in May 2026 as the first aldosterone synthase inhibitor for hypertension, used in combination with other antihypertensives in adults who are not adequately controlled.

  31. 2026AstraZeneca

    $15 Billion China Investment Through 2030

    AstraZeneca announces on 29 January 2026 that it will invest $15 billion in China through 2030 to expand manufacturing and research, in a market that is its second largest and about 12% of revenue.

  32. 2026Cloudflare

    VoidZero Acquisition and Growth Acceleration

    Cloudflare acquired VoidZero, the company behind the Vite JavaScript tooling ecosystem, in June 2026 and reported Q2 2026 revenue growth of 36%.

Acquisitions

AstraZeneca

  • EsoBiotec2025$1B
  • Fusion Pharmaceuticals2024$2B
  • Gracell Biotechnologies2024$1.2B
  • CinCor Pharma2023$1.8B
  • Alexion Pharmaceuticals2021$39B
  • Almirall Respiratory Portfolio2014$2.1B
All AstraZeneca acquisitions

Cloudflare

  • Human Native2026Undisclosed
  • Astro Technology Company2026Undisclosed
  • VoidZero2026Undisclosed
  • Replicate2025Undisclosed
  • Nefeli Networks2024Undisclosed
  • Baselime2024Undisclosed
All Cloudflare acquisitions

Questions about AstraZeneca vs Cloudflare

Who is the CEO of AstraZeneca PLC and Cloudflare, Inc.?

AstraZeneca PLC is led by Pascal Soriot and Cloudflare, Inc. is led by Matthew Prince. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.

When was AstraZeneca PLC founded vs Cloudflare, Inc.?

AstraZeneca PLC was founded in 1999 — 10 years before Cloudflare, Inc., which was founded in 2009. AstraZeneca PLC's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Cloudflare, Inc..

How many employees does AstraZeneca PLC have compared to Cloudflare, Inc.?

AstraZeneca PLC employs approximately 96,100 people, while Cloudflare, Inc. employs approximately 5,156. AstraZeneca PLC has the larger workforce at 96,100 employees, compared to Cloudflare, Inc.'s 5,156. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).

Where are AstraZeneca PLC and Cloudflare, Inc. headquartered?

AstraZeneca PLC is headquartered in United Kingdom and Cloudflare, Inc. is headquartered in United States. Their different home markets mean they may face different regulatory frameworks, tax regimes, and currency exposure.

Who founded AstraZeneca PLC and Cloudflare, Inc.?

AstraZeneca PLC was founded by Sir David Barnes, Håkan Mogren. Cloudflare, Inc. was founded by Matthew Prince, Michelle Zatlyn, Lee Holloway.

Which company has a longer operating history — AstraZeneca PLC or Cloudflare, Inc.?

AstraZeneca PLC has been operating for approximately 27 years, making it the more established of the two companies. Cloudflare, Inc. has been in operation for around 17 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.

Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the AstraZeneca vs Cloudflare overview

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.